Sugi Predict

Sugi Predict / Compounds / SCHEMBL7859587

SCHEMBL7859587

SCHEMBL7859587

COC(=O)C(CCC(N)=O)N1Cc2c(N)cccc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.44
▸ RAB9A P51151 6/20 0.44
▸ KMT2A Q03164 6/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ THRB P10828 2/20 0.36
▸ ALOX15 P16050 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ TNF P01375 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18747985 0.91 NPC1 (0.43) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL10074197 0.91 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL7849187 0.91 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL2254579 0.89 NPC1 (0.47) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL7850983 0.87 MEN1 (0.38) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL502389 0.86 ALOX15 (0.46) KMT2ASMN1; SMN2MEN1MAPTGAA
SCHEMBL30001202 0.86 ALOX15 (0.46) KMT2ASMN1; SMN2MEN1MAPTGAA
SCHEMBL10192658 0.85 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL10192666 0.85 NPC1 (0.43) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL7857212 0.84 TNF (0.39) NPC1RAB9AKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111298127-A Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same 黄泳华 2020-06-19 — — CN claimed
WO-2024178067-A9 CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-02-06 — — WO disclosed
WO-2024178067-A1 CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-08-29 — — WO disclosed
CN-111298127-A Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same 黄泳华 2020-06-19 — — CN disclosed
US-20170107193-A1 CRYSTALLINE LENALIDOMIDE PROCESS SHILPA MEDICARE LIMITED (IN) 2017-04-20 — — US disclosed
US-20170107193-A1 CRYSTALLINE LENALIDOMIDE PROCESS SHILPA MEDICARE LIMITED (IN) 2017-04-20 — — US disclosed
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 — — US disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 — — US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 — — US disclosed
WO-2014155371-A2 CRYSTALLINE LENALIDOMIDE PROCESS SHILPA MEDICARE LIMITED (IN) 2014-10-02 — — WO disclosed
EP-2479172-B1 Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines CELGENE CORP (US) 2013-10-09 — — EP disclosed
EP-1797068-B1 PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES CELGENE CORP (US) 2013-10-09 — — EP disclosed
EP-2438053-B1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) 2013-09-11 — — EP disclosed
EP-2479172-A1 Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines CELGENE CORPORATION (US) 2012-07-25 — — EP disclosed
US-20120053159-A1 ISOTOPOLOGUES OF LENALIDOMIDE CELGENE CORPORATION 2012-03-01 — — US disclosed
US-7863451-B2 Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines CELGENE CORPORATION (US) 2011-01-04 — — US disclosed
WO-2010139266-A1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053159-A1 ISOTOPOLOGUES OF LENALIDOMIDE CDK4, SRMS, DAP3 NPC1 4197/4885RAB9A 2425/4885KMT2A 1463/4885
US-20170107193-A1 CRYSTALLINE LENALIDOMIDE PROCESS SF3B1, SF3B2, LAS1L NPC1 3278/4885RAB9A 2936/4885KMT2A 2269/4885
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS NPC1 1917/4885RAB9A 3181/4885KMT2A 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.